Oral Anti-Cancer Drugs - JA DME
Oral Anti-Cancer Drug Fees
Oral anti-cancer drugs are billed using the National Drug Code (NDC) number. Such drug fees are subject to change on a quarterly basis. Currently, these drugs meet the requirements for coverage under the Omnibus Budget Reconciliation Act of 1993 (OBRA '93).
Note: Noridian provides this information as a service to our customers. While we have made every effort to ensure the accuracy of this information up to our publication deadline, we are not responsible for any errors or subsequent changes. We do not guarantee eligibility for reimbursement based on using this information. Reimbursement is based on factors including, but not limited to: disease diagnosis, medical necessity for the DMEPOS item and the Medicare program coverage guidelines.
Inclusion or exclusion of a fee schedule amount for an item or service does not imply any health insurance coverage.
Quarter 1 = January 1 - March 31
Quarter 2 = April 1 - June 30
Quarter 3 = July 1 - September 30
Quarter 4 = October 1 - December 31
Last Updated Tue, 05 Jul 2022 13:13:59 +0000